Norah Terrault, MD, MPH

Dr. Norah Terrault is Professor of Medicine and Chief of Gastroenterology and Liver Diseases and Neil Kaplowitz Endowed Chair in Liver Diseases Research. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a Masters in Public Health at the University of California at Berkeley. Dr. Terrault has focused her clinical and research activities on viral hepatitis and steatotic liver disease (metabolic and alcohol-associated), especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and metabolic steatotic liver disease, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIDDK-supported Liver Cirrhosis Network and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored more than 450 peer-reviewed manuscripts, editorials, and invited reviews as well as co-authoring US national guidelines for treatment of chronic hepatitis B and C and alcohol-associated liver disease. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. Dr. Terrault is currently serving as the president of the American Association for the Study of Liver Diseases (AASLD). She is the founder of USC Project ECHO, a multifaceted program to train and support primary care physicians in California to care for patients with viral hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators.

• 1/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)
  NIH · R01AA030960 · Aug 1, 2023 – Jul 31, 2030 · Role: Principal Investigator
• Translational Research Training in Hepatology
  NIH · T32DK127977 · Jul 1, 2022 – Jun 30, 2027 · Role: Principal Investigator
• USC Cirrhosis Clinical Center
  NIH · U01DK130197 · Sep 22, 2021 – Aug 31, 2026 · Role: Principal Investigator
• Mechanisms of Advanced NAFLD Disparities in Hispanics: A Multi-level Analysis
  NIH · R01MD015971 · Jan 1, 2021 – Nov 30, 2026 · Role: Co-Principal Investigator
• Hepatitis B Research Network (HBRN): Natural History and Treatment Studies
  NIH · U01DK082944 · Sep 30, 2008 – May 31, 2021 · Role: Co-Principal Investigator
• Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
  NIH · U01DK061738 · Jun 15, 2002 – Jun 30, 2027 · Role: Principal Investigator

• Steatotic Liver Disease, Clinical Subtypes, and Adverse Perinatal Outcomes: The Prospective Fatty Liver in Pregnancy Study. Clin Gastroenterol Hepatol. 2026 Apr 20.. View in PubMed
• Metabolic Dysfunction and Alcohol-Associated Steatotic Liver Disease in Women: Epidemiology, Natural History, and Clinical Outcomes. Clin Gastroenterol Hepatol. 2026 Apr 13.. View in PubMed
• Shared principles within HBV guidelines: aligning clinical approach with differentiated care for global elimination. Lancet Gastroenterol Hepatol. 2026 Jun; 11(6):441-443.. View in PubMed
• Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort. J Hepatol. 2026 Jul; 85(1):61-70.. View in PubMed
• Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. cities. Ann Hepatol. 2026 Mar 11; 31(2):102200.. View in PubMed
• Sex-Specific Cardiometabolic Profiles and Severity of Liver Fibrosis. JAMA Netw Open. 2026 Mar 02; 9(3):e260863.. View in PubMed
• Progress Towards Elimination: Hepatitis B and C Among Children and Young Adults in Rural Mongolia. J Viral Hepat. 2026 Mar; 33(3):e70145.. View in PubMed
• A pilot randomized controlled trial of a transportation assistance program in liver transplant (TAP-LT) candidates. Liver Transpl. 2026 Feb 18.. View in PubMed
• Living liver donor safety: Preoperative aspects of living liver donation- Guidelines from the ILTS-iLDLT consensus conference. Liver Transpl. 2026 Jul 01; 32(7):1049-1065.. View in PubMed
• Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD. J Hepatol. 2026 Jul; 85(1):37-47.. View in PubMed
• Reply. Clin Gastroenterol Hepatol. 2026 Feb 11.. View in PubMed
• National trends in resmetirom prescriptions for metabolic dysfunction-associated steatohepatitis in the USA. Clin Mol Hepatol. 2026 Apr; 32(2):e185-e188.. View in PubMed
• Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease. Nat Rev Gastroenterol Hepatol. 2026 Apr; 23(4):355-367.. View in PubMed
• The Obstacle is the Way: Finding a Path to Hepatitis C Elimination. Clin Infect Dis. 2026 Jan 16; 81(Supplement_3):i47-i50.. View in PubMed
• Differential gastrointestinal mortality in Native Hawaiian/Pacific Islander and Asian subgroups in the U.S.: a cross-sectional analysis of national mortality surveillance data 2018-2023. Lancet Reg Health Am. 2026 Mar; 55:101372.. View in PubMed
• Evaluating metabolic dysfunction-associated steatotic liver disease, associated adverse pregnancy outcomes, and postpartum maternal course utilising transient elastography with controlled attenuation parameter in pregnancy: a prospective cohort study. Lancet Obstet Gynaecol Womens Health. 2026 Jan; 2(1):e33-e41.. View in PubMed
• Living liver donor safety: Intraoperative considerations in living liver donation-Guidelines from the ILTS-iLDLT group consensus conference 2025. Liver Transpl. 2026 Apr 01; 32(4):592-608.. View in PubMed
• Long-term considerations following living liver donation-Guidelines from the 2025 ILTS-iLDLT consensus conference on living liver donor safety. Liver Transpl. 2025 Dec 18.. View in PubMed
• Living liver donor safety: Early postoperative considerations of living liver donation guidelines from the ILTS-iLDLTG consensus conference. Liver Transpl. 2026 Jun 01; 32(6):913-924.. View in PubMed
• Technical systematic review supporting the 2025 AASLD Practice Guideline on management of chronic hepatitis B. Hepatology. 2026 04 01; 83(4):998-1019.. View in PubMed
• AASLD ISDA Practice Guideline on treatment of chronic hepatitis B. Hepatology. 2026 Apr 01; 83(4):974-997.. View in PubMed
• Reframing hepatitis B prophylaxis in recipients of liver transplant: Time to focus on cure. Liver Transpl. 2026 Apr 01; 32(4):499-500.. View in PubMed
• Differential Effects of Cardiometabolic Risk Factors on All-Cause Mortality in United States Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Clin Gastroenterol Hepatol. 2026 May; 24(5):1344-1353.. View in PubMed
• Neighborhood Social Cohesion Associated With Chronic Liver Disease Prevalence and All-Cause Mortality. Gastro Hep Adv. 2026; 5(1):100775.. View in PubMed
• Cardiometabolic risk factors and alcohol use among adults aged 20-25: A nationally representative US study. J Hepatol. 2026 Jan; 84(1):e16-e18.. View in PubMed
• SMART Steps to HBV Cure. Hepatology. 2025 Dec 01; 82(6):1405-1407.. View in PubMed
• Ultrasound of the rectus femoris as a novel tool to measure sarcopenia in pediatric chronic liver disease. Hepatol Commun. 2025 Sep 01; 9(9).. View in PubMed
• A call to reclassify the delta hepatitis virus as an orphan disease. Hepatol Commun. 2025 Jul 01; 9(7).. View in PubMed
• Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal. J Infect Dis. 2025 Jun 02; 231(5):1290-1298.. View in PubMed
• Challenges in applying MASLD risk algorithms in pregnancy: A call for adaptation and inclusion. J Hepatol. 2025 Nov; 83(5):e236-e237.. View in PubMed
• Living donor liver transplant for alcohol-associated hepatitis: considerations and global perspectives. Expert Rev Gastroenterol Hepatol. 2025 Apr-May; 19(5):481-493.. View in PubMed
• HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B. Hepatol Commun. 2025 Jun 01; 9(6).. View in PubMed
• Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States. Hepatol Commun. 2025 May 01; 9(5).. View in PubMed
• Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign-Born: The FOCUS-HBV Multicentre Cohort. Aliment Pharmacol Ther. 2025 Jun; 61(12):1913-1922.. View in PubMed
• Erratum: HDV RNA assays: Performance characteristics, clinical utility, and challenges. Hepatology. 2025 May 01; 81(5):E149.. View in PubMed
• Outcomes for Early Liver Transplantation for Alcohol-associated Liver Disease in High-acuity Liver Transplant Recipients With Alcohol Use Disorder. Transplant Direct. 2025 Apr; 11(4):e1776.. View in PubMed
• Longer travel and traffic are associated with adult liver transplant waitlist mortality in the United States. Am J Transplant. 2025 Jul; 25(7):1515-1525.. View in PubMed
• Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021. Hepatology. 2025 Nov 01; 82(5):1274-1286.. View in PubMed
• Quest for HBV functional cure: what have we learnt from silencing RNAs? Gut. 2025 Feb 06; 74(3):340-342. Terrault N , Lok AS . View in PubMed
• Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies. J Hepatol. 2025 Aug; 83(2):329-347.. View in PubMed
• Association of Alcohol and Incremental Cardiometabolic Risk Factors With Liver Disease: A National Cross-sectional Study. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2205-2213.. View in PubMed
• At the Crossroads of Health and Disease: Consequences of Fat in the Liver. Annu Rev Physiol. 2025 02; 87(1):325-352.. View in PubMed
• Update on Hepatorenal Syndrome: From Pathophysiology to Treatment. Annu Rev Med. 2025 01; 76(1):373-387.. View in PubMed
• Antivirals in Preventing Perinatal Transmission of Hepatitis B: Start and Stop Times are Shifting. Am J Gastroenterol. 2025 May 01; 120(5):1007-1008.. View in PubMed
• Epidemiology and Outcomes of Alcohol-Associated Hepatitis in Adolescents and Young Adults. JAMA Netw Open. 2024 12 02; 7(12):e2452459.. View in PubMed
• Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J Hepatol. 2025 Apr; 82(4):744-756.. View in PubMed
• Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study. Ann Intern Med. 2025 Jan; 178(1):139-142.. View in PubMed
• Health disparities in cirrhosis care and liver transplantation. Nat Rev Gastroenterol Hepatol. 2025 Feb; 22(2):98-111.. View in PubMed
• The University of Southern California psychosocial checklist: A novel tool to remotely screen transplant candidates with alcohol-associated liver disease prior to hospital transfer. Liver Transpl. 2025 Feb 01; 31(2):250-253.. View in PubMed
• Safety of acamprosate for alcohol use disorder after liver transplant: A pilot randomized controlled trial. Liver Transpl. 2025 Apr 01; 31(4):498-507.. View in PubMed
• Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study. Hepatology. 2025 May 01; 81(5):1553-1563.. View in PubMed
• Use of HBsAg-positive donors in liver transplantation: An ILTS-EASL-AASLD multisociety survey. Liver Transpl. 2024 11 01; 30(11):1116-1122.. View in PubMed
• The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints. Am J Gastroenterol. 2025 Mar 01; 120(3):570-575.. View in PubMed
• The Survival Benefit of Reabstinence After Harmful Alcohol Use Following Early Liver Transplant for Severe Alcohol-Associated Hepatitis: A Multicenter ACCELERATE Study. Am J Gastroenterol. 2025 Apr 01; 120(4):827-836.. View in PubMed
• The impact of surging transplantation of alcohol-associated liver disease on transplantation for HCC and other indications. Hepatol Commun. 2024 07 01; 8(7).. View in PubMed
• Neighborhood-level Social Determinants of Health and Waitlist Mortality for Liver Transplantation: The Liver Outcomes and Equity Index. Transplantation. 2024 07 01; 108(7):1558-1569.. View in PubMed
• Liver transplantation for alcohol-associated liver disease. Hepatology. 2024 12 01; 80(6):1441-1461.. View in PubMed
• Reply: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB. Hepatology. 2024 Nov 01; 80(5):E82-E84.. View in PubMed
• Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nat Rev Gastroenterol Hepatol. 2024 Sep; 21(9):626-645.. View in PubMed
• Treatment of Hepatitis D – A Future Role for Combination Therapy. N Engl J Med. 2024 07 11; 391(2):181-183.. View in PubMed
• The obstacle is the way: Finding a path to hepatitis C elimination. Hepatology. 2024 07 01; 80(1):3-7.. View in PubMed
• Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis. J Infect Dis. 2024 May 08; 229(Supplement_3):S322-S327.. View in PubMed
• PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024 Nov 01; 80(5):1212-1226.. View in PubMed
• Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes. Clin Infect Dis. 2024 04 10; 78(4):983-990.. View in PubMed
• Maternal neighbourhood-level social determinants of health and their association with paediatric hepatitis C screening among children exposed to hepatitis C in pregnancy. Paediatr Perinat Epidemiol. 2024 02; 38(2):152-160.. View in PubMed
• Country-Specific Screening, Prevalence, and Immunity Rates for Hepatitis B Infection in a Large US Safety-Net System. Open Forum Infect Dis. 2024 Jan; 11(1):ofad699.. View in PubMed
• Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition”: EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024 07; 81(1):e20-e21.. View in PubMed
• Reply: ‘From NAFLD to MASLD: Promise and pitfalls of a new definition’ †. Hepatology. 2024 02 01; 79(2):E16-E17.. View in PubMed
• Reply to: “From NAFLD to MASLD: Promise and pitfalls of a new definition’. Ann Hepatol. 2024 Jul-Aug; 29(4):101178.. View in PubMed
• Low frequency of HBsAg reemergence in liver transplant recipients after stopping hepatitis B immune globulin: Implications for prophylaxis protocols. Liver Transpl. 2024 06 01; 30(6):668-671.. View in PubMed
• Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024 03 01; 79(3):E93-E94.. View in PubMed
• Peginterferon as Part of a Functional Cure Strategy for Hepatitis B: Is the Juice Worth the Squeeze? J Clin Exp Hepatol. 2024 Jan-Feb; 14(1):101300. Zhang TP, Terrault NA . . . View in PubMed
• Reply: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence, severity, and long-term outlook for SLD and subclassifications. Hepatology. 2024 Apr 01; 79(4):E117-E118.. View in PubMed
• Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study. Am J Transplant. 2024 Mar; 24(3):468-478.. View in PubMed
• Hepatitis C. Lancet. 2023 09 23; 402(10407):1085-1096.. View in PubMed
• National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature. Hepatology. 2024 03 01; 79(3):666-673.. View in PubMed
• Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women. Clin Gastroenterol Hepatol. 2024 02; 22(2):339-346.e5.. View in PubMed
• ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2024 01 01; 119(1):30-54.. View in PubMed
• Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with “Ludwig disease”. Hepatology. 2024 01 01; 79(1):E5-E6.. View in PubMed
• A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024 02 01; 79(2):502-523.. View in PubMed
• Association of nativity with survival among adults with hepatocellular carcinoma. J Natl Cancer Inst. 2023 07 06; 115(7):861-869.. View in PubMed
• Global importance of new treatment strategies to efforts to control hepatitis B virus. Expert Rev Anti Infect Ther. 2023 Jul-Dec; 21(8):847-862.. View in PubMed
• Association of Alanine Aminotransferase Flares to Hepatitis B Surface Decline During Tenofovir Alone or With Pegylated Interferon Alfa. Am J Gastroenterol. 2023 11 01; 118(11):2075-2079.. View in PubMed
• Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. AIDS. 2023 08 01; 37(10):1535-1543.. View in PubMed
• Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Hepatology. 2023 11 01; 78(5):E91-E92.. View in PubMed
• Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 12 01; 78(6):E103-E104. Rinella ME, Terrault N , Neuschwander-Tetr . View in PubMed
• Universal Adult Hepatitis B Screening and Vaccination as the Path to Elimination. JAMA. 2023 05 16; 329(19):1639-1640.. View in PubMed
• National Trends in Alcohol Use, Metabolic Syndrome, and Liver Disease From 1999 to 2018. Ann Intern Med. 2023 06; 176(6):879-882.. View in PubMed
• Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. Gastroenterology. 2023 08; 165(2):463-472.e5.. View in PubMed
• Use of HBV RNA and to predict change in serological status and disease activity in CHB. Hepatology. 2023 11 01; 78(5):1542-1557.. View in PubMed
• Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.. View in PubMed
• Population-attributable risk of modifiable lifestyle factors to hepatocellular carcinoma: The multi-ethnic cohort. Aliment Pharmacol Ther. 2023 07; 58(1):89-98.. View in PubMed
• Prevalence, Risk Profiles, and National Implications of Nonalcoholic Fatty Liver Disease in Pregnant Individuals. Clin Gastroenterol Hepatol. 2024 01; 22(1):194-196.e1.. View in PubMed
• Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol. 2023 08; 79(2):576-580.. View in PubMed
• Liver transplantation for alcohol-associated liver disease: A call for national standards of best practices to monitor and bridge disparities in access and outcomes. Am J Transplant. 2023 08; 23(8):1097-1101.. View in PubMed
• Healthcare affordability and effects on mortality among adults with liver disease from 2004 to 2018 in the United States. J Hepatol. 2023 08; 79(2):329-339.. View in PubMed
• Global epidemiology of cirrhosis – aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023 06; 20(6):388-398.. View in PubMed
• Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system. Hepatol Commun. 2023 04 01; 7(4).. View in PubMed
• Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO-PLUS study. J Viral Hepat. 2023 05; 30(5):397-405.. View in PubMed
• Reproductive health and liver disease: a patient-friendly summary of the 2021 AASLD guidance. Clin Liver Dis (Hoboken). 2023 Jan; 21(1):19-35.. View in PubMed

• Ou, Jing-Hsiung
• Lee, Brian
• Zhou, Kali
• Dodge, Jennifer
• Klausner, Jeffrey
• Golden, Lucy